# Breathe Biomedical — Healthcare Investment Intelligence

> diagnostics. MedFuel Intel profile as of 2026-06-12.

Breathe BioMedical is developing a breath analytics platform technology using infrared spectroscopy to detect diseases like early-stage breast cancer in women with dense breast tissue as an adjunct to mammography, achieving 88.2% accuracy in recent studies unaffected by breast density[1][2]. The technology samples, digitizes, and analyzes volatile organic compounds (VOCs) in exhaled breath with machine learning to identify biomarkers[4].

## Key facts (as of 2026-06-12)
- Sector: diagnostics
- Website: https://breathebiomedical.com/

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/breathe-biomedical-1. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.